<DOC>
	<DOC>NCT02104557</DOC>
	<brief_summary>Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception And Management Of Endometriosis-Associated Pain</brief_summary>
	<brief_title>Post Marketing Surveillance Study For Sayana®</brief_title>
	<detailed_description>Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who randomly visit the site who meet the inclusion/exclusion criteria.</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Subjects or legally authorized representatives of pediatric subjects agree to provide written informed consent form (ie, data privacy statement). 2.Women subjects who are initiating treatment with Sayana® for the first time as per the local product document for usage Known or suspected pregnancy. Undiagnosed vaginal bleeding. Known or suspected malignancy of breast. Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease. Significant liver disease. Known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients. Women who are before menarche or who are postmenopausal. Treatment with any investigational agent or device within 30 days prior to the enrollment visit.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sayana</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Contraception</keyword>
	<keyword>Endometriosis-associated pain</keyword>
	<keyword>PMS</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>